Phaseline

Targets › HTR3D

HTR3D (5-hydroxytryptamine receptor 3D): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Dec 2026.

Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons. (UniProt, Q70Z44)

Open in Phaseline: the race on HTR3D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Seoul National University HospitalRamosetron
Serotonin 3 (5-HT3) receptor antagonist
HTR3A, HTR3E, HTR3B, HTR3D, HTR3CPhase 2Fecal IncontinenceDec 2026

Conditions

Fecal Incontinence (1)

Modalities

small molecule (1)

Companies

Seoul National University Hospital (1)

Related targets

HTR3A (1) HTR3E (1) HTR3B (1) HTR3C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.